Europe pen needles Market

The Europe pen needles market is projected to reach USD 1.10 billion by 2031 from USD 0.72 billion in 2026 at a CAGR of 8.9% during the forecast period.

The Europe pen needles market is driven by the increasing prevalence of diabetes, a significant rise in insulin pen adoption, and advancements toward safe, thinner, and painless needle technologies that improve patient adherence. The growing elderly population and strong reimbursement support in major countries further boost demand. However, market growth faces constraints from pricing pressures, tender-based procurement, low-cost alternatives, and an increased focus on reusable devices to reduce needlestick injuries and needle use. Despite these challenges, there are lucrative opportunities for developing ultra-thin needles, safety-engineered needles, and sustainable, eco-friendly designs, especially with the rising use of GLP-1 and biologic injectables delivered via pens. Additionally, increased adoption of home care and digital training tools offer new advantages for manufacturers across Europe.

To know about the assumptions considered for the study download the pdf brochure

This report segments the pen needles market by type, length, application, mode of purchase, setting, and region.

Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), MTD Medical Technology and Devices (Italy), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US).

b. braun se (germany)

As a leader in pen needle manufacturing, B. Braun maintains its position in the Europe pen needles market with undisputed and historic leadership in both injection and infusion technologies. The company has a reputable history across Europe of producing high-quality, safety-engineered products. It leverages extensive knowledge in needle design, ergonomics, and patient safety to develop pen needles that are reliable, low-pain, and widely accepted in diabetes care. Its strong distribution network, partnerships with hospitals, and compliance with some of the highest European regulatory standards further solidify its market presence. Additionally, B. Braun's continuous innovation allows it to produce sustainable, competitively priced products, making it a preferred supplier in tender-driven healthcare systems. By combining these strengths, B. Braun maintains a significant influence and steady market share in the European pen needles market.

novo nordisk a/s (denmark)

Novo Nordisk, one of the most established companies in Europe, has a significant presence in the pen needle market for diabetes due to its diversified insulin portfolio, which drives demand for its proprietary pen needles. The company has a long history in diabetes management, strong clinical relationships, and extensive patient education programs that foster high trust and widespread acceptance. Novo Nordisk Pen Needles are known for their precise engineering, consistent quality, and comfort-focused designs, all aimed at improving adherence. Its comprehensive approach of integrating drugs, delivery devices, and training provides a competitive edge over standalone competitors. With wide distribution across Europe, investments in safety and ultra-thin needle technologies, and alignment with rising GLP-1 usage, Novo Nordisk is well-positioned in the European pen needle market.

Embecta Corp. (US)

Embecta has a strong legacy from the BD diabetes care division, making it a key player in Europe's pen needles market. The company boasts some of the widest installations globally. It offers reliable, precision-engineered pen needles known for consistent performance, safety, and patient comfort—crucial factors in Europe's quality-focused healthcare systems. Embecta could benefit from long-term partnerships with clinicians, pharmacies, and tender-based procurement agencies to deepen its market reach in the region. Its diverse product range also supports the management of insulin, GLP-1, and other injectable therapies, all relevant to Europe's rising chronic disease burden. Continued investments in safety features, ongoing manufacturing improvements, and patient support programs strengthen Embecta's competitive position in Europe's pen needle market. 

Market Ranking

The Europe pen needles market is competitive, with prominent players accounting for 29.1% of the total market share in 2025. Some of the players dominating the market include Embecta Corp., Novo Nordisk, B.Braun, Terumo Corporation, and Nipro Corporation, among others.

The most prominent European players in the pen needle market mainly target developed countries like Germany, France, and the UK, where advanced healthcare infrastructure and strong reimbursement systems make adoption easier. Recently, however, some small regional manufacturers have entered the market with high-quality, low-cost pen needles designed for local procurement needs. Over time, emerging companies have begun to compete more aggressively with global leaders in terms of price, product differentiation, and niche innovation. Also, the increasing shift toward home-care treatment and digital pharmacy channels in Europe presents opportunities for both established and new players to strengthen their regional presence.

Related Reports:

Europe Pen Needles Market By Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-like Peptide-1 Therapy), Mode of Purchase (Over-the-counter Purchase, Online Purchase) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com